Business
Alnylam is a global commercial-stage biopharma company focused on RNA interference medicines, using siRNA to silence disease-linked messenger RNA.
Alnylam revenue rose 65.2% to $3.71B, turning net income positive at $313.7M and free cash flow positive at $465.4M.
The read at a glance✓ Audited against SEC data
- Business mix — RNAi therapeutics platformNote
- Revenue — Revenue rose 65.2% to $3.71BOK
- Profitability — Net income turned positiveOK
- Cash — Free cash flow was $465.4MOK
- Equity — Equity rose to $789.2MOK
- Insiders — 0 buys / 48 sellsWatch
- Accounting — Altman-Z distress; EQ safeWatch
Where the revenue comes from
Fiscal 2025, as ALNYLAM PHARMACEUTICALS, INC. reports it. History and quarterly detail are in the app.
- Net product revenues$3.0B
- TTR$2.5B
- AMVUTTRA$2.3B
- Net revenues from collaborations$553.4M
- Rare$499.9M
Leadership changes
From ALNYLAM PHARMACEUTICALS, INC.'s own filings, the day they're filed.
- Phillip A. Sharp · Directors · departureeff. 2025-05-08
- Marsha H. Fanucci · Directors · departureeff. 2023-09-29
- Peter N. Kellogg · departureeff. 2023-09-29
Latest filings
- 10-Q · Quarterly report2026-07-30
- 8-K · Company announcement2026-07-30
- 8-K · Company announcement2026-05-27
- 10-Q · Quarterly report2026-04-30
- 8-K · Company announcement2026-04-30
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ALNYLAM PHARMACEUTICALS, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.